3Q Financial Markets Preview: Waiting for the Fall

Almost across the board, buysiders and bankers expect biotech to do well toward the end of the third quarter. But everyone, they say, will simply have to grit their teeth to get through the choppiness and typical summer slowdown expected in the interim.

A few fundamentals seem firmly in place to give the sector a leg up. In particular, insiders expect the juggernaut of M&A and partnerships to be a secular trend, giving the sector enhanced visibility and luring generalists back to the group. ...